Discussion
impairment of skin barrier function, xerosis, cutaneous disorder
PROLIFERATION, XEROSIS
The impairment of skin barrier function is a common cutaneous disorder raising challenges for dermatologists, patients, and the cosmetic industry. Increasing advancements in elucidating the mechanism of action for strengthening skin barrier provide promising interventions for the management of these individualsIn this study, in vitro experiments substantiated that the fermented cultures of E06 and E12 each displayed promising DPPH scavenging capacities. The investigational strains can produce many antioxidative agents including superoxide dismutase, glutathione peroxidase, multivitamins, and etcetera after fermentation. DPPH is a kind of free radical. It is probably that the scavenging agents existing in fermented cultures reacted with the DPPH. Furthermore, using Furthermore, the lysates of both E06 and E12 both enhanced the proliferation of HaCaT cells, and the promotion of proliferation was closely correlated with the concentration of the lysate. The lysates of E06 and E12 also conferred a protective effect on HaCaT cells, ameliorating the loss of cell viability caused by Subsequently, we performed a clinical study to investigate whether the lotion containing VHProbi® Mix R could strengthen the skin barrier function or not. The water retention capacity of skin, including the TEWL and moisturization, was markedly improved following treatment with the investigational product. The indictor of TEWL represents the water loss of skin through epidermis. The decrease of TEWL indicates the recovery of skin barrier integrity. And the skin moisturization indicates the water content of skin stratum corneum. A better recovery of TEWL would lead to an increase of skin moisturization. An impaired skin barrier function is mostly associated with the xerosis, or “dry” skin, giving rise to an increase in TEWLIn recent years, topical postbiotic applications have attracted considerable attention from scientific and industrial communities. Gueniche et al. conducted an in vitro study and a human trial using The field of postbiotics is continuously evolving. Increasing clinical and experimental research provides evidence that postbiotics can not only exert healthy effects on gastrointestinal function, but can also be used for dermal application owing to their distinctive properties. Given these aspects, the development of postbiotics for topical applications represents a promising treatment and/or intervention for the management of skin barrier function. However, there are some limitations in this study, including the absence of a control group and placebo effects in the clinical trial, no elucidation of the skin microbiota variations in the subjects, and only a relatively short duration of the intervention was examined. We acknowledged that the rigorous evidence may not be obtained from this study due to lacking the placebo group. Some positive changes for the subjects using the investigational products from baseline to the endpoint of the study would lay foundation for us conducting a randomized, placebo control trail.